Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T16:03:46.845Z.
Calculation as of: 2026-10-06T16:03:46.845Z.
Quote observation: 2026-10-06T15:59:07.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: f6adff8253f4c85dc5eb0f5c76b7f284768243a99251a0912c87940a98678e1d
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Market Cap
$10.52M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$10.06M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$10.01M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Lifeward Ltd. (LFWD) | $10.55M | N/A | N/A | N/A | N/A |
| Polyrizon Ltd. (PLRZ)vs › | $10.53M | N/A | N/A | N/A | N/A |
| CytoMed Therapeutics Limited (GDTC)vs › | $10.52M | N/A | N/A | N/A | N/A |
| Caring Brands, Inc. (CABR)vs › | $10.68M | N/A | N/A | N/A | N/A |
| Satellos Bioscience Inc. (MSLE)vs › | $10.44M | N/A | N/A | N/A | N/A |
| Lisata Therapeutics, Inc. (LSTA)vs › | $10.93M | N/A | N/A | N/A | N/A |
| BioVie Inc. (BIVI)vs › | $11.08M | N/A | N/A | N/A | N/A |
| Medicus Pharma Ltd. Common Stock (MDCX)vs › | $10.06M | N/A | N/A | N/A | N/A |
| NeuroOne Medical Technologies Corporation (NMTC)vs › | $10.01M | N/A | N/A | N/A | N/A |
| Kiora Pharmaceuticals, Inc. (KPRX)vs › | $11.30M | N/A | 12.81x | 12.81x | 12.81x |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
